Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Cancers · 27.06.2025 · 17 (13) · 2165
DOI: 10.3390/cancers17132165 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.06.2025. Verfasst von Demis Pitoni und 9 weiteren Autor:innen. Beteiligte Einrichtung: IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1) Background and Aims: Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) face a significantly increased risk of malignancies, including a 10-fold higher risk for colorectal cancer (CRC) and a lifetime risk for cholangiocarcinoma (CCA) exceeding 20%. The mechanisms underlying this elevated risk remain elusive. This review consolidates recent findings on cancer risk in PSC-IBD patients, focusing on molecular pathways, diagnostic innovations, and prevention strategies. (2)
Methods
A comprehensive PubMed search was performed to identify studies published through to March 2025 on oncogenic processes, molecular mechanisms, and advancements in diagnostic and preventive strategies for CRC and CCA in PSC-IBD patients. (3)
Results
Surveillance guidelines recommend an annual colonoscopy for CRC and imaging combined with CA 19-9 monitoring for CCA. Recent studies highlight the role of molecular alterations, including epigenetic modifications, in tumorigenesis. Advances in molecular diagnostics, imaging, and endoscopic technologies are improving the accuracy and timeliness of cancer detection. (4)
Conclusions
PSC-IBD patients remain at high risk for CRC and CCA, emphasizing the need for vigilant surveillance and advanced prevention strategies. Advances in early detection and precision diagnostics offer new opportunities to reduce the cancer burden in this high-risk population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
- Department of Medical Sciences, Division of Gastroenterology, University of Torino, 10126 Torino, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
ORCID-Profile: Arianna Dal Buono, Roberto Gabbiadini, Vincenzo Ronca, Francesca Colapietro, Nicola Pugliese, Davide Giuseppe Ribaldone, Cristina Bezzio, Ana Lleo, Alessandro Armuzzi
Zitieren
APA
Pitoni, D., Dal Buono, A., Gabbiadini, R., Ronca, V., Colapietro, F., Pugliese, N., Ribaldone, D. G., Bezzio, C., Lleo, A., & Armuzzi, A. (2025). Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Cancers, 17(13), 2165. https://doi.org/10.3390/cancers17132165
Vancouver
Pitoni D, Dal Buono A, Gabbiadini R, Ronca V, Colapietro F, Pugliese N, et al. Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Cancers. 2025;17(13):2165. doi:10.3390/cancers17132165
BibTeX
@article{Pitoni2025,
author = {Pitoni, Demis and Dal Buono, Arianna and Gabbiadini, Roberto and Ronca, Vincenzo and Colapietro, Francesca and Pugliese, Nicola and Ribaldone, Davide Giuseppe and Bezzio, Cristina and Lleo, Ana and Armuzzi, Alessandro},
title = {Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis},
journal = {Cancers},
year = {2025},
volume = {17},
number = {13},
pages = {2165},
doi = {10.3390/cancers17132165}
}
EUVIMED